ASCO 2025: Focus on Treatment Sequencing in mBC

Advertisement
Kelly McCann, MD, PhDHR Breast Cancer | July 7, 2025
Dr. Kelly McCann reviews sequencing and emerging therapies in HR-positive, HER2-negative metastatic breast cancer.
Kelly McCann, MD, PhDHER2 Breast Cancer | July 7, 2025
Dr. Kelly McCann of UCLA details HER2-positive breast cancer sequencing and toxicity management.
Kelly McCann, MD, PhDTriple-Negative Breast Cancer | July 7, 2025
Dr. Kelly McCann discusses evolving treatment sequencing strategies in metastatic triple-negative breast cancer.
William J. Gradishar, MDHER2 Breast Cancer | June 5, 2025
Dr. Gradishar discusses how tolerability, toxicity, and NCCN guidelines shape HER2+ breast cancer treatment decisions.
William J. Gradishar, MDHER2 Breast Cancer | June 5, 2025
Dr. William Gradishar discusses treatment sequencing strategies for HER2+ metastatic breast cancer at ASCO 2025.
Advertisement